SERDA therapeutics submits IND for wound debridement agent
Clinical studies are expected to start in Q2 2023.
Clinical studies are expected to start in Q2 2023.
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
Ayurveda is one of the most advanced sciences of its times
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
Cipla has received 8 inspectional observations in Form 483
Subscribe To Our Newsletter & Stay Updated